Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Anesthesiology ; 107(2): 232-8, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17667566

RESUMO

BACKGROUND: Cardiopulmonary bypass induces a nonspecific inflammatory response. Procalcitonin has been advocated as a specific biomarker for infection. The authors studied the accuracy of procalcitonin to diagnose postoperative infection after cardiac surgery and compared it with those of C-reactive protein, white blood cell count, and interleukins 6 and 8. METHODS: The authors prospectively included 100 patients scheduled to undergo elective cardiac procedures with cardiopulmonary bypass. Blood samples were taken before surgery and each day over the 7-day postoperative period, and measurement of procalcitonin, C-reactive protein, white blood cell count, and interleukins 6 and 8 were performed. Diagnosis of infection was performed by a blinded expert panel. Data are expressed as value [95% confidence interval]. RESULTS: Infection was diagnosed in 16 patients. Procalcitonin was significantly higher in infected patients, with a peak reached on the third postoperative day. Only the areas under the receiver operating curve of procalcitonin (0.88 [0.71-0.95]) and C-reactive protein (0.72 [0.58-0.82]) were significantly different from the no-discrimination curve, and that of procalcitonin was significantly different from those of C-reactive protein, white blood cell count, and interleukins 6 and 8. A procalcitonin value greater than 1.5 ng/ml beyond the second day diagnosed postoperative infection with a sensitivity of 0.93 [0.70-0.99] and a specificity of 0.80 [0.70-0.87]. Procalcitonin was significantly higher in patients who died (27.5 [1.65-40.5] vs. 1.2 [0.7-1.5] ng/ml; P < 0.001). CONCLUSION: Procalcitonin is a valuable marker of bacterial infections after cardiac surgery.


Assuntos
Infecções Bacterianas/diagnóstico , Calcitonina/sangue , Ponte Cardiopulmonar/efeitos adversos , Complicações Pós-Operatórias/diagnóstico , Precursores de Proteínas/sangue , Infecções Bacterianas/sangue , Biomarcadores/sangue , Proteína C-Reativa , Peptídeo Relacionado com Gene de Calcitonina , Procedimentos Cirúrgicos Eletivos/métodos , Feminino , Humanos , Interleucina-6/sangue , Interleucina-8/sangue , Contagem de Leucócitos/métodos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/sangue , Valor Preditivo dos Testes , Estudos Prospectivos , Curva ROC , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Fatores de Tempo
2.
Tunis Med ; 83(8): 473-6, 2005 Aug.
Artigo em Francês | MEDLINE | ID: mdl-16238275

RESUMO

Our purpose was to assess the effects of corticotherapy prescribed after delivery on the kinetic of biological parameters of HELLP syndrome (hemolysis elevated liver enzymes low platelets count). Twenty patients in whom pregnancy was complicated by antepartum or postpartum Hellp Syndrome, were randomised to receive, after delivery, either 12 mg of Dexamethasone every 12 hours for two doses (Group C, n=10), or a placebo (Group T, n=10). Biological parameters of the Hellp syndrome were analysed just before the first bolus of either treatment (H0), then after 24, 36, 48 and 72 hours. The corticotherapy was more efficient than placebo, in the correction of the biological parameters of the hellp syndrome. It permitted a rapid correction of the thrombopenia (from the 24th hour) but its effect on hemolysis marker was later (from the 36th hour). The kinetic of the hepatic cytolysis marker was not modified by corticotherapy. Finally, the administration of corticosteroids does not reduce maternal morbidity related to HELLP Syndrome.


Assuntos
Dexametasona/uso terapêutico , Glucocorticoides/uso terapêutico , Síndrome HELLP/tratamento farmacológico , Adulto , Interpretação Estatística de Dados , Dexametasona/administração & dosagem , Método Duplo-Cego , Feminino , Glucocorticoides/administração & dosagem , Síndrome HELLP/diagnóstico , Humanos , Paridade , Placebos , Período Pós-Parto , Gravidez , Estudos Prospectivos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...